WEBSITE BSE:532872 NSE: SUNPHA ADV Inc. Year: 2006 Industry: Business Support My Bucket: Add Stock
Last updated: 15:56
Sun Pharma Advanced Research Company Ltd is engaged in the research and development on natural sciences and engineering (Pharmacy). The Company operates via Pharmaceuticals Research & Development section. Its programs consist of Xelpros, Elepsia XR, Baclofen GRS, Paclitaxel Injection Concentrate for Nanodispersion (Taclantis), Salmeterol - Fluticasone Dry Powder Inhaler (DPI), SUN-K706, Brimonidine OD, Tizanidine ER, Minocycline Topical and SUN-597 Topical. Xelpros is a Benzalkonium Chloride (BAK)-free Latanoprost eye drops developed with its S...Read More
Sun Pharma Advanced Research Company Ltd is engaged in the research and development on natural sciences and engineering (Pharmacy). The Company operates via Pharmaceuticals Research & Development section. Its programs consist of Xelpros, Elepsia XR, Baclofen GRS, Paclitaxel Injection Concentrate for Nanodispersion (Taclantis), Salmeterol - Fluticasone Dry Powder Inhaler (DPI), SUN-K706, Brimonidine OD, Tizanidine ER, Minocycline Topical and SUN-597 Topical. Xelpros is a Benzalkonium Chloride (BAK)-free Latanoprost eye drops developed with its Swollen Micelle Microemulsion (SMM) generation. Elepsia XR is a once-a-day method of Levetiracetam, an antiepileptic agent. Baclofen GRS is a once-a-day formula of Baclofen, a centrally acting, antispasmodic drug. Taclantis is a Cremophor and Albumin free method. Its DPI is a premetered, 60 doses, breath activated tool to manage combination of Salmeterol and Fluticasone by way of inhalation. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹4520 Cr.
Stock P/E -13.2
P/B -10.6
Current Price ₹139.3
Book Value ₹ -13.1
Face Value 1
52W High ₹204.3
Dividend Yield 0%
52W Low ₹ 108.2
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 | 8 | 8 |
| Other Income | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 | 0 | 0 |
| Total Income | 30 | 20 | 21 | 18 | 13 | 15 | 27 | 19 | 8 | 8 |
| Total Expenditure | 113 | 116 | 122 | 110 | 116 | 89 | 80 | 62 | 74 | 65 |
| Operating Profit | -83 | -96 | -101 | -92 | -103 | -74 | -53 | -43 | -66 | -57 |
| Interest | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12 |
| Profit Before Tax | -86 | -100 | -105 | -96 | -107 | -79 | -61 | -52 | -76 | -80 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 |
| Profit After Tax | -86 | -100 | -106 | -96 | -107 | -80 | -60 | -52 | -76 | -80 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -86 | -100 | -106 | -96 | -107 | -80 | -60 | -52 | -76 | -80 |
| Adjusted Earnings Per Share | -2.7 | -3.1 | -3.3 | -3 | -3.3 | -2.5 | -1.8 | -1.6 | -2.3 | -2.5 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Net Sales | 239 | 76 | 72 | 53 |
| Other Income | 11 | 29 | 2 | 9 |
| Total Income | 250 | 105 | 74 | 62 |
| Total Expenditure | 453 | 478 | 395 | 281 |
| Operating Profit | -203 | -373 | -321 | -219 |
| Interest | 8 | 2 | 9 | 28 |
| Depreciation | 12 | 13 | 12 | 12 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -12 |
| Profit Before Tax | -223 | -387 | -343 | -269 |
| Provision for Tax | 0 | 0 | -0 | -1 |
| Profit After Tax | -223 | -387 | -343 | -268 |
| Adjustments | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -223 | -387 | -343 | -268 |
| Adjusted Earnings Per Share | -6.9 | -11.9 | -10.6 | -8.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -5% | 0% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -10% | -11% | -4% | -7% |
| ROE Average | 0% | -55% | -55% | -55% |
| ROCE Average | -312% | -155% | -155% | -155% |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Shareholder's Funds | 513 | 126 | -217 |
| Minority's Interest | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 100 |
| Other Non-Current Liabilities | 138 | 123 | 76 |
| Total Current Liabilities | 179 | 265 | 374 |
| Total Liabilities | 830 | 514 | 333 |
| Fixed Assets | 106 | 108 | 99 |
| Other Non-Current Assets | 269 | 137 | 208 |
| Total Current Assets | 455 | 269 | 26 |
| Total Assets | 830 | 514 | 333 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 5 |
| Cash Flow from Operating Activities | -69 | -429 | -360 |
| Cash Flow from Investing Activities | -548 | 392 | 158 |
| Cash Flow from Financing Activities | 617 | 42 | 199 |
| Net Cash Inflow / Outflow | -1 | 5 | -3 |
| Closing Cash & Cash Equivalent | 1 | 5 | 2 |
| # | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Earnings Per Share (Rs) | -6.86 | -11.93 | -10.55 |
| CEPS(Rs) | -6.5 | -11.55 | -10.17 |
| DPS(Rs) | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 15.8 | 3.88 | -6.69 |
| Core EBITDA Margin(%) | -89.65 | -532.26 | -450.27 |
| EBIT Margin(%) | -90.02 | -509.81 | -465.04 |
| Pre Tax Margin(%) | -93.22 | -512.05 | -477.64 |
| PAT Margin (%) | -93.22 | -512.56 | -477.26 |
| Cash Profit Margin (%) | -88.29 | -496 | -459.99 |
| ROA(%) | -26.81 | -57.63 | -80.88 |
| ROE(%) | -43.41 | -121.28 | 0 |
| ROCE(%) | -41.91 | -112.35 | -311.92 |
| Receivable days | 50.01 | 116.55 | 80.33 |
| Inventory Days | 0 | 0 | 0 |
| Payable days | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 0 |
| Price/Book(x) | 11.36 | 95.47 | -22.14 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | 23.92 | 157.49 | 70.5 |
| EV/Core EBITDA(x) | -28.11 | -31.93 | -15.74 |
| Net Sales Growth(%) | 0 | -68.36 | -5 |
| EBIT Growth(%) | 0 | -79.18 | 13.34 |
| PAT Growth(%) | 0 | -73.96 | 11.55 |
| EPS Growth(%) | 0 | -73.96 | 11.55 |
| Debt/Equity(x) | 0 | 0.37 | -1.19 |
| Current Ratio(x) | 2.54 | 1.02 | 0.07 |
| Quick Ratio(x) | 2.54 | 1.02 | 0.07 |
| Interest Cover(x) | -28.15 | -227.27 | -36.92 |
| Total Debt/Mcap(x) | 0 | 0 | 0.05 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 |
| FII | 3.3 | 3.23 | 2.64 | 2.15 | 2.23 | 1.45 | 1.47 | 1.76 | 2.04 | 2.04 |
| DII | 0.67 | 0.67 | 0.17 | 0.22 | 0.62 | 1.12 | 0.96 | 1.04 | 0.78 | 0.87 |
| Public | 30.36 | 30.42 | 31.52 | 31.96 | 31.48 | 31.76 | 31.89 | 31.53 | 31.51 | 31.42 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 21.31 | 21.31 | 21.31 | 21.31 | 21.31 | 21.31 | 21.31 | 21.31 | 21.31 | 21.31 |
| FII | 1.07 | 1.05 | 0.86 | 0.7 | 0.72 | 0.47 | 0.48 | 0.57 | 0.66 | 0.66 |
| DII | 0.22 | 0.22 | 0.05 | 0.07 | 0.2 | 0.36 | 0.31 | 0.34 | 0.25 | 0.28 |
| Public | 9.85 | 9.87 | 10.23 | 10.37 | 10.22 | 10.31 | 10.35 | 10.23 | 10.23 | 10.2 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 32.45 | 32.45 | 32.45 | 32.45 | 32.45 | 32.45 | 32.45 | 32.45 | 32.45 | 32.45 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
